Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103+ dendritic cells in late-stage ovarian cancer

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Flies, Dallas B ^a   Higuchi, Tomoe ^a   Harris, Jaryse C ^a   Jha, Vibha ^b,c   Gimotty, Phyllis A ^b   Adams, Sarah F ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Arapahoe Community College Littleton   (United States)

Author keywords

CD103+; dendritic cells; Lair 1; ovarian cancer; PD 1; T cell exhaustion; tumor microenvironment

Indexed keywords

CD103 ANTIGEN; CD11 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL MODEL; ARTICLE; ASCITES; CELL SURVIVAL; CLINICAL ARTICLE; DENDRITIC CELL; FEMALE; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; OVARY CANCER; TUMOR MICROENVIRONMENT;

EID: 84979999678     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1185583     Document Type: Article

References (45)

1. R.L.Siegel, K.D.Miller, A.Jemal. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30; PMID:26742998; http://dx.doi.org/10.3322/caac.21349
2. U.K.Scarlett, J.R.Conejo-Garcia. Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert Rev Obstet Gynecol 2012; 7:413-9; PMID:24039628; http://dx.doi.org/10.1586/eog.12.41
3. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
4. R.Yigit, L.F.Massuger, C.G.Figdor, R.Torensma. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117:366-72; PMID:20144842; http://dx.doi.org/10.1016/j.ygyno.2010.01.019
5. V.Lavoué, A.Thédrez, J.Levêque, F.Foucher, S.Henno, V.Jauffret, M.A.Belaud-Rotureau, V.Catros, F.Cabillic. Immunity of human epithelial ovarian carcinoma:the paradigm of immune suppression in cancer. J Transl Med 2013; 11:147; PMID:23763830; http://dx.doi.org/10.1186/1479-5876-11-147
6. B.H.Nelson. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008; 222:101-16; PMID:18363996; http://dx.doi.org/10.1111/j.1600-065X.2008.00614.x
7. K.Schlienger, C.S.Chu, E.Y.Woo, P.M.Rivers, A.J.Toll, B.Hudson, M.V.Maus, J.L.Riley, Y.Choi, G.Coukos et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517-27; PMID:12684428
8. J.R.Cubillos-Ruiz, P.C.Silberman, M.R.Rutkowski, S.Chopra, A.Perales-Puchalt, M.Song, S.Zhang, S.E.Bettigole, D.Gupta, K.Holcomb et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 2015; 161:1527-38; PMID:26073941; http://dx.doi.org/10.1016/j.cell.2015.05.025
9. T.J.Curiel, S.Wei, H.Dong, X.Alvarez, P.Cheng, P.Mottram, R.Krzysiek, K.L.Knutson, B.Daniel, M.C.Zimmermann et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562-7; PMID:12704383
10. J.Duraiswamy, G.J.Freeman, G.Coukos. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900-12; PMID:23975756; http://dx.doi.org/10.1158/0008-5472.CAN-13-1550
11. J.Krempski, L.Karyampudi, M.D.Behrens, C.L.Erskine, L.Hartmann, H.Dong, E.L.Goode, K.R.Kalli, K.L.Knutson. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011; 186:6905-13; PMID:21551365; http://dx.doi.org/10.4049/jimmunol.1100274
12. U.K.Scarlett, M.R.Rutkowski, A.M.Rauwerdink, J.Fields, X.Escovar-Fadul, J.Baird, J.R.Cubillos-Ruiz, A.C.Jacobs, J.L.Gonzalez, J.Weaver et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:22351930; http://dx.doi.org/10.1084/jem.20111413
13. E.Huarte, J.R.Cubillos-Ruiz, Y.C.Nesbeth, U.K.Scarlett, D.G.Martinez, R.J.Buckanovich, F.Benencia, R.V.Stan, T.Keler, P.Sarobe et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res 2008; 68:7684-91; PMID:18768667; http://dx.doi.org/10.1158/0008-5472.CAN-08-1167
14. S.Peter, G.Bak, K.Hart, B.Berwin. Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion. Transl Oncol 2009; 2:291-9; PMID:19956391; http://dx.doi.org/10.1593/tlo.09190
15. L.Karyampudi, P.Lamichhane, J.Krempski, K.R.Kalli, M.D.Behrens, D.M.Vargas, L.C.Hartmann, J.M.Janco, H.Dong, K.E.Hedin et al. PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-κB. Cancer Res 2016; 76:239-50; PMID:26567141; http://dx.doi.org/10.1158/0008-5472.CAN-15-0748
16. A.R.Sánchez-Paulete, F.J.Cueto, M.Martínez-López, S.Labiano, A.Morales-Kastresana, M.E.Rodríguez-Ruiz, M.Jure-Kunkel, A.Azpilikueta, M.A.Aznar, J.I.Quetglas et al. Cancer immunotherapy with immunomodulatory Anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016; 6:71-9; PMID:26493961; http://dx.doi.org/10.1158/2159-8290.CD-15-0510
17. M.L.Broz, M.Binnewies, B.Boldajipour, A.E.Nelson, J.L.Pollack, D.J.Erle, A.Barczak, M.D.Rosenblum, A.Daud, D.L.Barber et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014; 26:638-52; PMID:25446897; http://dx.doi.org/10.1016/j.ccell.2014.09.007
18. B.Ruffell, D.Chang-Strachan, V.Chan, A.Rosenbusch, C.M.Ho, N.Pryer, D.Daniel, E.S.Hwang, H.S.Rugo, L.M.Coussens. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 2014; 26:623-37; PMID:25446896; http://dx.doi.org/10.1016/j.ccell.2014.09.006
19. C.A.Dutertre, L.F.Wang, F.Ginhoux. Aligning bona fide dendritic cell populations across species. Cell Immunol 2014; 291:3-10; PMID:25262488; http://dx.doi.org/10.1016/j.cellimm.2014.08.006
20. B.U.Schraml, C.Reis e Sousa. Defining dendritic cells. Curr Opin Immunol 2015; 32:13-20; PMID:25553392; http://dx.doi.org/10.1016/j.coi.2014.11.001
21. A.Bachem, S.Güttler, E.Hartung, F.Ebstein, M.Schaefer, A.Tannert, A.Salama, K.Movassaghi, C.Opitz, H.W.Mages et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348
22. O.P.Joffre, E.Segura, A.Savina, S.Amigorena. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254
23. E.Hartung, M.Becker, A.Bachem, N.Reeg, A.Jäkel, A.Hutloff, H.Weber, C.Weise, C.Giesecke, V.Henn et al. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR1. J Immunol 2015; 194:1069-79; PMID:25520399; http://dx.doi.org/10.4049/jimmunol.1401903
24. K.F.Roby, C.C.Taylor, J.P.Sweetwood, Y.Cheng, J.L.Pace, O.Tawfik, D.L.Persons, P.G.Smith, P.F.Terranova. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21:585-91; PMID:10753190; http://dx.doi.org/10.1093/carcin/21.4.585
25. D.C.Connolly, R.Bao, A.Y.Nikitin, K.C.Stephens, T.W.Poole, X.Hua, S.S.Harris, B.C.Vanderhyden, T.C.Hamilton. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63:1389-97; PMID:12649204
26. L.Meyaard, G.J.Adema, C.Chang, E.Woollatt, G.R.Sutherland, L.L.Lanier, J.H.Phillips. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 1997; 7:283-90; PMID:9285412; http://dx.doi.org/10.1016/S1074-7613(00)80530-0
27. L.Meyaard. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol 2008; 83:799-803; PMID:18063695
28. M.Son, F.Santiago-Schwarz, Y.Al-Abed, B.Diamond. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc Natl Acad Sci U S A 2012; 109:E3160-7; PMID:23093673; http://dx.doi.org/10.1073/pnas.1212753109
29. M.Son, B.Diamond. C1q-mediated repression of human monocytes is regulated by leukocyte-associated Ig-like receptor 1 (LAIR-1). Mol Med 2014; 20:559-68; PMID:25247291; http://dx.doi.org/10.2119/molmed.2014.00185
30. + nonlymphoid dendritic cells. Immunity 2012; 37:60-73; PMID:22795876; http://dx.doi.org/10.1016/j.immuni.2012.04.012
31. E.van der Aa, N.van Montfoort, A.M.Woltman. BDCA3(+)CLEC9A(+) human dendritic cell function and development. Semin Cell Dev Biol 2015; 41:39-48; PMID:24910448; http://dx.doi.org/10.1016/j.semcdb.2014.05.016
32. S.I.Labidi-Galy, V.Sisirak, P.Meeus, M.Gobert, A.B.Treilleux, J.-D.Combes, J.Faget, F.Mithieux, A.Cassignol, O.Tredan et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 17:5423-34; PMID:21697280; http://dx.doi.org/10.1158/0008-5472.CAN-11-0367
33. + dendritic cells from mouse bone marrow. Blood 2014; 124:3081-91; PMID:25100743; http://dx.doi.org/10.1182/blood-2013-12-545772
34. T.Okazaki, T.Honjo. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27:195-201; PMID:16500147; http://dx.doi.org/10.1016/j.it.2006.02.001
35. L.T.Nguyen, P.S.Ohashi. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 2015; 15:45-56; PMID:25534622; http://dx.doi.org/10.1038/nri3790
36. E.J.Wherry. T cell exhaustion. Nat Immunol 2011; 12:492-9; PMID:21739672
37. K.E.Pauken, E.J.Wherry. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015; 36:265-76; PMID:25797516; http://dx.doi.org/10.1016/j.it.2015.02.008
38. L.E.Kandalaft, G.T.Motz, J.Duraiswamy, G.Coukos. Tumor immune surveillance and ovarian cancer:lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011; 30:141-51; PMID:21298574; http://dx.doi.org/10.1007/s10555-011-9289-9
39. Y.Nesbeth, U.Scarlett, J.Cubillos-Ruiz, D.Martinez, X.Engle, M.J.Turk, J.R.Conejo-Garcia. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 2009; 69:6331-8; PMID:19602595; http://dx.doi.org/10.1158/0008-5472.CAN-08-4329
40. U.K.Scarlett, J.R.Cubillos-Ruiz, Y.C.Nesbeth, D.G.Martinez, X.Engle, A.T.Gewirtz, C.L.Ahonen, J.R.Conejo-Garcia. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009; 69:7329-37; PMID:19738057; http://dx.doi.org/10.1158/0008-5472.CAN-09-0835
41. J.R.Cubillos-Ruiz, X.Engle, U.K.Scarlett, D.Martinez, A.Barber, R.Elgueta, L.Wang, Y.Nesbeth, Y.Durant, A.T.Gewirtz et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009; 119:2231-44; PMID:19620771; http://dx.doi.org/10.1172/JCI37716
42. T.Higuchi, D.B.Flies, N.A.Marjon, G.Mantia-Smaldone, L.Ronner, P.A.Gimotty, S.F.Adams. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res 2015; 3:1257-68; PMID:26138335; http://dx.doi.org/10.1158/2326-6066.CIR-15-0044
43. C.O.Park, T.S.Kupper. The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med 2015; 21:688-97; PMID:26121195; http://dx.doi.org/10.1038/nm.3883
44. K.Staveley-O'Carroll, T.D.Schell, M.Jimenez, L.M.Mylin, M.J.Tevethia, S.P.Schoenberger, S.S.Tevethia. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 2003; 171:697-707; PMID:12847236; http://dx.doi.org/10.4049/jimmunol.171.2.697
45. D.B.Flies, S.Wang, H.Xu, L.Chen. Cutting edge:A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol (Baltimore, Md:1950) 2011; 187:1537-41; http://dx.doi.org/10.4049/jimmunol.1100660